Download PDF

Journal of Biomedical Science

, Volume 13, Issue 3, pp 419–432 | Cite as

Breast cancer risk associated with genotypic polymorphism of the genes involved in the estrogen-receptor-signaling pathway: a multigenic study on cancer susceptibility

  • Jyh-Cherng Yu
  • Huan-Ming Hsu
  • Shou-Tung Chen
  • Giu-Cheng Hsu
  • Chiun-Sheng Huang
  • Ming-Feng Hou
  • Yi-Ping Fu
  • Ting-Chih Cheng
  • Pei-Ei Wu
  • Chen-Yang Shen
Article
First Online:
Received:
Accepted:

Summary

The reproductive hormone, estrogen, contributes to the development of breast cancer by binding to the estrogen receptor (ER) in the nucleus, triggering cell growth and tumor promotion. In addition to its role in regulating target genes and signaling pathways involved in cell cycle progression, the ER-signaling pathway may regulate the expression of chromatin-remodeling gene, Metastasis-associated 3 (MTA3), or interact with chromatin-remodeling protein, Metastasis-associated 1 (MTA1). The invasion-suppressor gene, E-Cadherin (E-Cad), has recently been identified as a downstream target gene regulated by the ER-MTA3 pathway via the transcriptional repressor, Snail, and the ER-MTA3-Snail-E-Cad pathway has therefore been evoked to explain the clinical observation that ER expression in breast cancer is generally associated with a better clinical outcome. Since E-Cad may play an initiating role during breast tumorigenesis, we hypothesized that this ER-signaling pathway may also determine susceptibility to breast cancer, and examined this in a multigenic case–control study of 468 incident breast cancer patients and 470 healthy controls by genotyping the single nucleotide polymorphisms (SNPs) in five genes (ER, MTA3, Snail, E-Cad, and MTA1) in the ER-signaling pathways. Support for this hypothesis came from the observations that (a)␣with the exception of Snail, which interacted differently with reproductive risk factors in relation to breast cancer risk, there was a joint effect of the SNPs of these genes and estrogen-related risk factors (age at first full-term pregnancy and obesity, measured by the body mass index) on breast cancer risk (p < 0.05); (b) a trend toward increased risk of developing breast cancer was seen in women harboring a greater number of putative high-risk genotypes of these genes in ER-signaling pathways; (c) this association between risk and the number of putative high-risk genotypes was stronger and more significant in women thought to have experienced higher estrogen level, i.e., obese women; and (d) the risk effect conferred by obesity was only significant in women with a higher number of putative high-risk genotypes of the ER-signaling genes. These epidemiological findings highlight the role of newly identified novel ER-related pathways in breast cancer development and provide a more comprehensive picture of the tumorigenic effect of estrogen in breast cancer development.

Key words:

breast cancer E-cadherin estrogen estrogen receptor genetic polymorphism MTA1 MTA3 snail 
Download to read the full article text

References

  1. 1.
    Hulka B.S., Stark A.T. (1995). Breast cancer: cause and prevention. Lancet 346:883–887PubMedCrossRefGoogle Scholar
  2. 2.
    Kelsey J.L., Gammon M.D., John E.M. (1993). Reproductive factors and breast cancer. Epidemiol. Rev. 15:36–47PubMedGoogle Scholar
  3. 3.
    Pike M.C., Spicer D.V., Dahmoush L., Press M.F. (1993). Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 15:17–35PubMedGoogle Scholar
  4. 4.
    Gruber C.J., Tschugguel W., Schneeberger C., Huber J.C. (2002). Production and actions of estrogens. N. Engl. J. Med. 346:340–352PubMedCrossRefGoogle Scholar
  5. 5.
    Dickson R.B., Stancel G.M. (2000). Estrogen receptor-mediated processes in normal and cancer cells. J. Natl. Cancer Inst. Monogr. 27:135–145PubMedGoogle Scholar
  6. 6.
    Frasor J., Danes J.M., Komm B., Chang K.C., Lyttle C.R., Katzenellenbogen B.S. (2003). Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144:4562–4574PubMedCrossRefGoogle Scholar
  7. 7.
    Fujita N., Kajita M., Taysavang P., Wade P.A. (2004). Hormonal regulation of metastasis-associated protein 3 transcription in breast cancer cells. Mol. Endocrinol. 18:2937–2949PubMedCrossRefGoogle Scholar
  8. 8.
    Fujita N., Jaye D.L., Kajita M., Geigerman C., Moreno C.S., Wade P.A. (2003). MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell. 113:207–219PubMedCrossRefGoogle Scholar
  9. 9.
    Kumar R., Wang R.A., Bagheri-Yarmand R. (2003). Emerging roles of MTA family members in human cancers. Semin. Oncol. 30 (5 Suppl 16):30–37PubMedCrossRefGoogle Scholar
  10. 10.
    Batlle E., Sancho E., Franci C., Dominguez D., Monfar M., Baulida J., Garcia De Herreros A. (2000). The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2:84–89PubMedCrossRefGoogle Scholar
  11. 11.
    Fearon E.R. (2003). Connecting estrogen receptor function, transcriptional repression, and E-cadherin expression in breast cancer. Cancer Cell 3:307–310PubMedCrossRefGoogle Scholar
  12. 12.
    Kumar R. (2003). Another tie that binds the MTA family to breast cancer. Cell 113:142–143PubMedCrossRefGoogle Scholar
  13. 13.
    Ding S.L., Sheu L.F., Yu J.C., Yang Y.L., Chen B., Leu F.J., Shen C.Y. (2004). Expression of estrogen receptor-alpha and Ki67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma. J. Biomed. Sci. 11:911–919PubMedGoogle Scholar
  14. 14.
    Gold B., Kalush F., Bergeron J., Scott K., Mitra N., Wilson K., Ellis N., Huang H., Chen M., Lippert R., Halldorsson B.V., Woodworth B., White T., Clark A.G., Parl F.F., Broder S., Dean M., Offit K. (2004). Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res. 64:8891–8900PubMedCrossRefGoogle Scholar
  15. 15.
    Shen C.Y., Yu J.C., Lo Y.L., Kuo C.H., Yue C.T., Jou Y.S., Huang C.S., Lung J.C., Wu C.W. (2000). Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma- an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res. 60:3884–3892PubMedGoogle Scholar
  16. 16.
    Cheng C.W., Wu P.E., Yu J.C., Huang C.S., Yue C.T., Wu C.W., Shen C.Y. (2001). Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 20:3814–3823PubMedCrossRefGoogle Scholar
  17. 17.
    Guilford P., Hopkins J., Harraway J., McLeod M., McLeod N., Harawira P., Taite H., Scoular R., Miller A., Reeve A.E. (1998). E-cadherin germline mutations in familial gastric cancer. Nature 392:402–405PubMedCrossRefGoogle Scholar
  18. 18.
    Kumar R., Wang R.A., Mazumdar A., Talukder A.H., Mandal M., Yang Z., Bagheri-Yarmand R., Sahin A., Hortobagyi G., Adam L., Barnes C.J., Vadlamudi R.K. (2002). A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 418:654–657PubMedCrossRefGoogle Scholar
  19. 19.
    Yang P.S., Yang T.L., Liu C.L., Wu C.W., Shen C.Y. (1997). A case–control study of breast cancer in Taiwan. Br. J. Cancer 75:752–756PubMedGoogle Scholar
  20. 20.
    Lo Y.L., Yu J.C., Huang C.S., Tseng S.L., Chang T.M., Chang K.J., Wu C.W., Shen C.Y. (1998). Allelic loss of the BRCA1 and BRCA2 genes and other regions on 17q and 13q in breast cancer among women from Taiwan (area of low incidence but early onset). Int. J. Cancer 79:580–587PubMedCrossRefGoogle Scholar
  21. 21.
    Huang C.S., Chern H.D., Chang K.J., Cheng C.W., Hsu S.M., Shen C.Y. (1999). Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 59:4870–4875PubMedGoogle Scholar
  22. 22.
    Cheng T.C., Chen S.T., Huang C.S., Fu Y.P., Yu J.C., Cheng C.W., Wu P.E., Shen C.Y. (2005). Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. Int. J. Cancer 113:345–353PubMedCrossRefGoogle Scholar
  23. 23.
    Lung J.C., Chu J.S., Yu J.C., Yue C.T., Lo Y.L., Shen C.Y., Wu C.W. (2002). Aberrant expression of cell cycle regulator cyclin D1 in breast cancer is related to chromosomal genomic instability. Gene Chromosom Cancer 34:276–284CrossRefGoogle Scholar
  24. 24.
    Fu Y.P., Yu J.C., Cheng T.C., Lou M.A., Hsu G.C., Wu C.Y., Chen S.T., Wu H.S., Wu P.E., Shen C.Y. (2003). Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility. Cancer Res. 63:2440–2446PubMedGoogle Scholar
  25. 25.
    Lo Y.L., Yu J.C., Chen S.T., Yang H.C., Fann C.S., Mau Y.C., Shen C.Y. (2005). Breast cancer risk associated with genotypic polymorphism of the mitosis-regulating gene Aurora-A/STK15/BTAK. Int. J. Cancer 115:276–283PubMedCrossRefGoogle Scholar
  26. 26.
    Li L.C., Chui R.M., Sasaki M., Nakajima K., Perinchery G., Au H.C., Nojima D., Carroll P., Dahiya R. (2000). A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res. 60:873–876PubMedGoogle Scholar
  27. 27.
    Shin Y., Kim I.J., Kang H.C., Park J.H., Park H.W., Jang S.G., Lee M.R., Jeong S.Y., Chang H.J., Ku J.L., Park J.G. (2004). A functional polymorphism (−347 G–>GA) in the E-cadherin gene is associated with colorectal cancer. Carcinogenesis 25:2173–2176PubMedCrossRefGoogle Scholar
  28. 28.
    Ohnishi Y., Tanaka T., Ozaki K., Yamada R., Suzuki H., Nakamura Y. (2001). A high-throughput SNP typing system for genome-wide association studies. J. Hum. Genet. 46:471–477PubMedCrossRefGoogle Scholar
  29. 29.
    Sellers T.A. (2004). Genetic Ancestry and Molecular Epidemiology. Cancer Epidemiol. Biomarkers Prev. 13:499–500PubMedGoogle Scholar
  30. 30.
    Kleinbaum DG, Kupper LL, Morgenstern KH. Epidemiologic Research : Principles and Quantitative Methods. Van Nostrand Reinhold NY, 1982Google Scholar
  31. 31.
    Kleinbaum DG, Kupper LL, Muller KE. Applied regression analysis and other multivariable methods. PWS-KENT Publishing Company Boston, 1998Google Scholar
  32. 32.
    Vineis P. (2004). Individual susceptibility to carcinogens. Oncogene 23:6477–6483PubMedCrossRefGoogle Scholar
  33. 33.
    Russo J., Tay L.K., Russo I.H. (1982). Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res. Treat. 2:5–73PubMedCrossRefGoogle Scholar
  34. 34.
    Johnston S.R., Dowsett M. (2003). Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat. Rev. Cancer 3:821–831PubMedCrossRefGoogle Scholar
  35. 35.
    Smith I.E., Dowsett M. (2003). Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348:2431–2442PubMedCrossRefGoogle Scholar
  36. 36.
    Kim M.J., Cardiff R.D., Desai N., Banach-Petrosky W.A., Parsons R., Shen M.M., Abate-Shen C. (2002). Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA 99:2884–2889PubMedCrossRefGoogle Scholar
  37. 37.
    Roberts C.W., Orkin S.H. (2004). The SWI/SNF complex-chromatin and cancer. Nat. Rev. Cancer 4:133–142PubMedGoogle Scholar
  38. 38.
    Versteege I., Sevenet N., Lange J., Rousseau-Merck M.F., Ambros P., Handgretinger R., Aurias A., Delattre O. (1998). Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394:203–206PubMedCrossRefGoogle Scholar
  39. 39.
    Gunduz E., Gunduz M., Ouchida M., Nagatsuka H., Beder L., Tsujigiwa H., Fukushima K., Nishizaki K., Shimizu K., Nagai N. (2005). Genetic and epigenetic alterations of BRG1 promote oral cancer development. Int. J. Oncol. 26:201–210PubMedGoogle Scholar
  40. 40.
    Medina P.P., Carretero J., Fraga M.F., Esteller M., Sidransky D., Sanchez-Cespedes M. (2004). Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. Genes Chromosomes Cancer 41:170–177PubMedCrossRefGoogle Scholar
  41. 41.
    Bau D.T., Fu Y.P., Chen S.T., Cheng T.C., Yu J.C., Wu P.E., Shen C.Y. (2004). Breast cancer risk and the DNA double-strand break end-joining capacity of non-homologous end-joining genes are affected by BRCA1. Cancer Res 64:5013–5019PubMedCrossRefGoogle Scholar
  42. 42.
    Hazan R.B., Qiao R., Keren R., Badano I., Suyama K. (2004). Cadherin switch in tumor progression. Ann. NY Acad. Sci. 1014:155–163PubMedCrossRefGoogle Scholar
  43. 43.
    Hatsell S., Rowlands T., Hiremath M., Cowin P. (2003). Beta-catenin and Tcfs in mammary development and cancer. J. Mammary Gland Biol. Neoplasia 8:145–158PubMedCrossRefGoogle Scholar
  44. 44.
    Guilford P. (1999). E-cadherin downregulation in cancer: fuel on the fire? Mol. Med. Today 5:172–177PubMedCrossRefGoogle Scholar
  45. 45.
    Okubo T., Truong T.K., Yu B., Itoh T., Zhao J., Grube B., Zhou D., Chen S. (2001). Down-regulation of promoter 1.3 activity of the human aromatase gene in breast tissue by zinc-finger protein, snail (SnaH). Cancer Res. 61:1338–1346PubMedGoogle Scholar

Copyright information

© National Science Council Taipei 2006

Authors and Affiliations

  • Jyh-Cherng Yu
    • 1
  • Huan-Ming Hsu
    • 1
    • 2
  • Shou-Tung Chen
    • 3
  • Giu-Cheng Hsu
    • 4
  • Chiun-Sheng Huang
    • 5
  • Ming-Feng Hou
    • 6
  • Yi-Ping Fu
    • 2
  • Ting-Chih Cheng
    • 2
  • Pei-Ei Wu
    • 2
  • Chen-Yang Shen
    • 2
    • 7
  1. 1.Departments of SurgeryTri-Service General HospitalTaipeiTaiwan
  2. 2.Institute of Biomedical SciencesAcademia SinicaTaipeiTaiwan
  3. 3.Division of General Surgery, Department of SurgeryChanghua Christian HospitalChanghuaTaiwan
  4. 4.Department of RadiologyTri-Service General HospitalTaipeiTaiwan
  5. 5.Department of SurgeryNational Taiwan University HospitalTaipeiTaiwan
  6. 6.Department of SurgeryKaohsiung Medical University HospitalKaohsiungTaiwan
  7. 7.Life Science LibraryAcademia SinicaTaipeiTaiwan

Personalised recommendations